Lancet 393:3139 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
How do you use Lemon Bottle fat dissolving
[27] [7] Patients should report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
GH secretagogues are contraindicated in patients with active cancer or a history of recent cancer because of the risk of recurrence
Rare but serious risks include pancreatitis, gallbladder disease, and thyroid tumors (seen in animal studies, not confirmed in humans but flagged by the FDA)